Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Longmu Zhuanggu Granules is a traditional Chinese patent medicine (TCM) developed and manufactured by Jianmin Pharmaceutical Group. It is a multi-herbal and mineral combination formulation widely used in China to support bone health, treat and prevent rickets and osteomalacia, and promote overall growth and development in children. The formulation combines traditional Chinese herbs (such as Codonopsis root, Astragalus root, Ophiopogon tuber, softshell turtle shell, fossilized dragon bone, jujube fruit, and licorice root) with Western nutritional supplements (including calcium lactate, calcium gluconate, and vitamin D2). It is indicated for children with weak muscle and bone development, delayed growth, and calcium deficiency, and is also used to strengthen the spleen and stomach, improve appetite, and manage symptoms like excessive night sweating, night terrors, and indigestion.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Longmu Zhuanggu Granules.